companydata.dkcompanydata.dk

FERTIN PHARMA A/S: Financial statements 2023

CVR: 25834844

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

FERTIN PHARMA A/S (CVR 25834844) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,012,566,000 and a net result of DKK -136,701,000 compared with DKK -91,376,000 the year before. That is an increase of 13.4% compared with the year before. The profit margin was -13.5%. Equity in the 2023 report amounted to DKK 458,408,000. The solvency ratio was 18.3%. The company had 654 employees in the financial year.

Revenue
DKK 1,012,566,000
Gross Profit
DKK 34,144,000
Profit/Loss
DKK -136,701,000
Equity
DKK 458,408,000
Total Assets
DKK 2,498,199,000
Employees
654

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20231B34.1M-136.7M458.4M654
2022892.6M25.2M-91.4M596.3M622
2021932.5M161.4M37.6M681.4M569
2020991.1M246.4M155.4M770.1M674
2019881.6M190.8M81.3M778.3M661

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Christopher Beck Lambert joins the board of FERTIN PHARMA A/SNov 1, 2023

As of November 1, 2023, Christopher Beck Lambert has joined the board of directors of FERTIN PHARMA A/S.

Michael Henrik Thomsen joins the board of FERTIN PHARMA A/SNov 1, 2023

As of November 1, 2023, Michael Henrik Thomsen has joined the board of directors of FERTIN PHARMA A/S.

Peter Halling leaves the board of FERTIN PHARMA A/SNov 1, 2023

As of November 1, 2023, Peter Halling has left the board of directors of FERTIN PHARMA A/S.

Michael Henrik Thomsen joins FERTIN PHARMA A/S as adm. dir.Nov 1, 2023

As of November 1, 2023, Michael Henrik Thomsen is registered as adm. dir. of FERTIN PHARMA A/S.

Peter Halling steps down as adm. dir. of FERTIN PHARMA A/SNov 1, 2023

As of November 1, 2023, Peter Halling has stepped down as adm. dir. of FERTIN PHARMA A/S.

Michael Henrik Thomsen leaves the board of FERTIN PHARMA A/SOct 31, 2023

As of October 31, 2023, Michael Henrik Thomsen has left the board of directors of FERTIN PHARMA A/S.

FERTIN PHARMA A/S: The 2022 annual report is outJun 30, 2023

FERTIN PHARMA A/S has published its annual report for 2022. Revenue came to DKK 892,580,000, and the net result was DKK -91,376,000.

About FERTIN PHARMA A/S

FERTIN PHARMA A/S is a Danish company of the type Aktieselskab based in Vejle, founded in 2001. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named JUT NR. 2128 A/S. The management consists of Michael Henrik Thomsen. The board consists of Christopher Beck Lambert (chair), Bo Korsgaard Jensen, Jovana Mejri and Michael Henrik Thomsen. The company is owned by Aspeya Inc.. The company has 959 employees (2026). In 2025, the company reported revenue of DKK 1,344,394,000 and a net result of DKK -280,841,000 compared with DKK -259,011,000 the year before. Equity in the 2025 report amounted to DKK 1,269,900,000.

Source: annual report 2025, Danish Business Authority